Home  »  Finance   »  Investors: What’s The Real Deal With BioNTech SE...

Investors: What’s The Real Deal With BioNTech SE (NASDAQ: BNTX)

The trading price of BioNTech SE (NASDAQ:BNTX) floating higher at last check on Wednesday, June 22, closing at $126.18, 2.38% higher than its previous close.

Traders who pay close attention to intraday price movement should know that it has been fluctuating between $122.39 and $131.02. The company’s P/E ratio in the trailing 12-month period was 2.28, while its 5Y monthly beta was -0.70. In examining the 52-week price action we see that the stock hit a 52-week high of $457.87 and a 52-week low of $119.72. Over the past month, the stock has lost -25.60% in value.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


BioNTech SE, whose market valuation is $30.91 billion at the time of this writing, is expected to release its quarterly earnings report Nov 09, 2021. The dividend yield on the company stock is 1.71%, while its Forward Dividend ratio is 2.11. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by $8.52 per share this quarter, however they have predicted annual earnings per share of $41.2 for 2021 and $39.67 for 2022. It means analysts are expecting annual earnings per share growth of 58,757.10% this year and -3.70% next year.

Analysts have forecast the company to bring in revenue of $4.57 billion for the current quarter, with the likely lows of $3.89 billion and highs of $6.07 billion. The average estimate suggests sales will likely up by 981.70% this quarter compared to what was recorded in the comparable quarter last year. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2021 is $19.64 billion. The company’s revenue is forecast to grow by 3,229.50% over what it did in 2021.

A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of BioNTech SE No upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest BNTX has a 100% Sell on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Sell, while an average of long term indicators suggests that the stock is currently 100% Sell.

Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned BNTX a recommendation rating is 15. Out of them, 8 rate it a Hold, while 6 recommend Buy, whereas 1 assign an Overweight rating. 0 analyst(s) have tagged BioNTech SE (BNTX) as Underweight, while 0 advise Sell. Analysts have rated the stock Overweight, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.

A quick review shows that BNTX’s price is currently -15.37% off the SMA20 and -16.45% off the SMA50. The RSI metric on the 14-day chart is currently showing 33.94, and weekly volatility stands at 5.50%. When measured over the past 30 days, the indicator reaches 5.07%. BioNTech SE (NASDAQ:BNTX)’s beta value is currently sitting at 0, while the Average True Range indicator is currently displaying 8.28. With analysts defining $159.26-$336.20 as the low and high price targets, we arrive at a consensus price target of $241.96 for the trailing 12-month period. The current price is about -26.22% off the estimated low and -166.44% off the forecast high, based on this estimate. Investors will be thrilled if BNTX’s share price rises to $240.92, which is the median consensus price. At that level, BNTX’s share price would be -90.93% below current price.

To see how BioNTech SE stock has been performing today in comparison to its peers in the industry, here are the numbers: BNTX stock’s performance was 2.38% at last check in today’s session, and -44.76% in the past year. BioNTech SE has a P/E ratio of 2.28. Also during today’s trading, the S&P 500 Index has surged 0.45%, while the Dow Jones Industrial also saw a positive session, up 0.23% today.

An evaluation of the daily trading volume of BioNTech SE (NASDAQ:BNTX) indicates that the 3-month average is 1.41 million.

Currently, records show that 243.12 million of the company’s shares remain outstanding. The insiders hold 62.87% of outstanding shares, whereas institutions hold 16.10%. However, since the stock’s price has seen -51.55% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.

Leave a Comment

Your email address will not be published.

Related Videos

Related Posts